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Abstract
Pyrrole-imidazole polyamides are versatile DNA minor groove binders and attractive thera-
peutic options against oncological targets, especially upon functionalization with an alkylat-
ing agent such as seco-CBI. These molecules also provide an alternative for oncogenes
deemed “undruggable” at the protein level, where the absence of solvent-accessible pock-
ets or structural crevices prevent the formation of protein-inhibitor ligands; nevertheless,
the genome-wide effect of pyrrole-imidazole polyamide binding remain largely unclear to-
date. Here we propose a next-generation sequencing-based workflow combined with
whole genome expression arrays to address such issue using a candidate anti-cancer
alkylating agent, KR12, against codon 12 mutant KRAS. Biotinylating KR12 enables the
means to identify its genome-wide effects in living cells and possible biological implications
via a coupled workflow of enrichment-based sequencing and expression microarrays. The
subsequent computational pathway and expression analyses allow the identification of its
genomic binding sites, as well as a route to explore a polyamide’s possible genome-wide
effects. Among the 3,343 KR12 binding sites identified in the human LS180 colorectal can-
cer genome, the reduction of KR12-bound gene expressions was also observed. Addition-
ally, the coupled microarray-sequencing analysis also revealed some insights about the
effect of local chromatin structure on pyrrole-imidazole polyamide, which had not been fully
understood to-date. A comparative analysis with KR12 in a different human colorectal can-
cer genome SW480 also showed agreeable agreements of KR12 binding affecting gene
expressions. Combination of these analyses thus suggested the possibility of applying this
approach to other pyrrole-imidazole polyamides to reveal further biological details about
the effect of polyamide binding in a genome.
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Introduction
While protein-level inhibitors aimed to inhibit enzyme activity or disrupt binding enjoy a large
degree of commercial success, pyrrole-imidazole polyamides (“PIPs”) and their accurate DNA
base pair recognition [1–5] provide a promising option against a large class of so-called
“undruggable” targets such as KRAS [6–8] which lack solvent-accessible surfaces or pockets for
ligand binding. From paired heterocyclic amide building blocks of pyrrole and imidazole, PIPs
can distinguish G/C and A/T (T/A) pairs via DNA minor groove binding with Im/Py and
Py/Py pairs, respectively, down to the precision of a single hydrogen bond between the bases.
Chemical functionalization provides versatility in regulating biological events [9–15] such as
cell reprogramming, NF-κB-dependent gene transcription, retinal development, and the inhi-
bition of specific biological targets [16, 17]. Nevertheless, as PIPs principally bind typically well
less than 20 bp, the impact of binding at genomic locations other than the intended design site
remains unclear to-date. Without exploring other possible binding sites, it may be too prema-
ture to conclude that unanticipated binding to non-KRAS loci has no effect, since off-target
effects could also contribute to cancer cell death and mask the true efficacy of a therapeutic
candidate. In spite of recent developments in next-generation sequencing, PIP binding studies,
especially those involving alkylating functional groups, remain few and far between at the
genome level. Hopefully with the procedure discussed in this manuscript, we can introduce a
useful addition in the design pipeline to understand whether off-target binding may have a
large effect on the tumor before more costly studies, e.g. animal models. Sequencing studies
involving bioactive DNA-targeting polyamides conjugated with a psoralenmoiety for photo-
crosslinking and biotin as affinity tag [18] so far have been largely restricted to chromatinized
regions in the living cell genome until the latest report with a 6-bp alkylating PIP [19], albeit in
an ex vivo setting. Following our previous study of a PIP with 9-bp recognition demonstrating
toxicity against KRASG12mutant cell lines [20], we seek to evaluate, via a new sequencing pro-
cedure with the biotinylated KR12 to affinity capture nucleotides bearing binding sites for the
polyamide in vivo, and computational workflow to determine whether other genomic binding
sites in living cells may present an issue in the effectiveness of alkylating PIPs as therapeutic
candidates. Corroborating findings here with our previous publication in which KR12 demon-
strated distinguishable toxicities in KRASG12D/G12V over wild-type cells suggested specific
targeting of the mutant driver gene by the polyamide. Results here also revealed, for the first
time at 9-bp precision, insights into the manner in which PIPs access the human genome in
cells.
Materials and Methods
General Materials and Computational Tools
Chemicals and molecular biology grade reagents were purchased from the following manufac-
turers: PyBOP and Fmoc-β-alanineWang resin, Novabiochem; HCTU, Peptide Institute Inc.
(Osaka, Japan); HPLC grade acetonitrile and biotin, Aldrich Chemicals; TrisHCl, NP-40, SDS,
EDTA, sodium bicarbonate, 25:24:1 phenol/chloroform/isoamyl alcohol, Nacalai Tesque; Tri-
ton-X 100, Complete Protease Inhibitor, Roche; HEPES, Gibco; pyrrole, imidazole, DIEA,
sodium chloride, PIPES, sodium acetate, and solvents (unless otherwise specified),Wako
Chemicals.
Computational utilities such as bedtools 2.25.0, samtools 1.3, bcftools 1.3, diffReps 1.55.4
and MACS 1.4.2 were used in conjunction with custom R 3.2 and Perl 5.16 scripts [21–29].
LS180 H3K27Ac ChIP-seq results were obtained from NCBI (GSM1890754). DNase I hyper-
sensitivity (digital DNaseI hypersensitivity clusters, DHS) and chromatin state segmentation
Identifying Pyrrole-Imidazole Polyamide Binding Sites from Sequencing Data
PLOS ONE | DOI:10.1371/journal.pone.0165581 October 31, 2016 2 / 19
Competing Interests: The authors have declared
that no competing interests exist.
(Broad ChromHMM) data [30, 31], in hg19 coordinates, were obtained from ENCODE [32].
RefSeq annotations and hg19 reference sequences (chr1-22 and X, Y, M) were sourced from
RefFlat information from University of California, Santa Cruz (UCSC) [33, 34]. The sequence
file for the LS180 genome was reassembled from CCLE sequencing results (G41705) from
CGHub [35] and reassembled by Picard 1.137 and GATK 3.4.46 to hg19 coordinates, with
indels ignored duringmulti-allelic variant calling by bcftools.
Synthesis of KR12
The backbone chain (ImPy-β-ImImPyIm-γ-PyIm-β-PyPy) for the (+) strand motif 5’-
TGWWGGCGW-3’ was synthesized in a stepwise Fmoc solid-phase synthesis reaction on a
PSSM-8 peptide synthesizer (Shimadzu) with a custom operating system on 10-μmol scale
with Fmoc-β-alanineWang resin. Cleavage from solid support was achieved with 0.5N
LiOH/NMP at 55°C for 1 h. Purification of the cleavage product was performed using high-
performance liquid chromatography on a LC-20 (Shimadzu), using a 10 mm × 150 mmGem-
ini-NX3u 5-ODS-H reverse-phase column (Phenomenex) using 0.1% acetic acid in Milli-Q
water and a linear gradient of 0–66.7% acetonitrile over 20 m at a flow rate of 10 ml m-1 with
detection at 310 nm. Collected fractions were analyzed by LC-MS2020 (Shimadzu). After puri-
fication, N-terminal biotinylation and C-terminal conjugation of seco-CBI to produce KR12
was achieved by incubating the cleavage product in the presence of biotin, PyBOP and DIEA
for 2 h to allow reaction; after the conversion of the C-terminal carboxylic acid to the activated
1-hydroxybenzotriazole ester, the reaction was mixed with 5.1 μmol NH2-seco-CBI in 100 μL
NMP [36] and stirred overnight to allow coupling. After solvent evaporation, the reaction
product was characterized and purified by liquid chromatography and a linear gradient of
0.1% acetic acid in 30%– 75% acetonitrile and water over 0.5 h with detection at 310 nm. The
final product (tR = 16.87 m) after purification was lyophilized and stored. ESI-TOF-MS
C100H110ClN34O18S m/z calcd [M+H]2+ 1071.95; found 1072.00, [M+3H]3+ 714.94; found
715.25.
Cell Cultures and Viability Assay
Colorectal adenocarcinoma LS180 and SW480 cells were cultured and maintained at 37°C, 5%
CO2 under humid conditions in Eagle’s Minimum Essential Medium (MEM, Gibco) and Dul-
becco’s Modified Eagle’s Medium (DMEM, Gibco), respectively. Media were additionally sup-
plemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Gibco). For
sequencing experiments, cultures were prepared in replicates at 6 × 105 cells/dish prior to
KR12 administration. For WST viability assays, cells were seeded at a final density of 103 cells
per sample in a 96-well plate for overnight attachment prior to treatment with 0.1% DMSO,
300 and 1000 nM KR12 as well as non-biotinylated variant (KR12 N/B) in 0.1% DMSO for 48
h to assess compound toxicity. After compound administration,WST-8 reagent (Dojindo) was
added to each sample for incubation at 37°C for 2 h prior to absorbancemeasurement at 450
nm on a MTP-310 photospectrometer (Corona).
Ion Torrent Sequencing
LS180 and SW480 cultures were treated with 500 nM KR12 in 0.05% DMSO for 6 h before
washing, detachment in ice-cold phosphate-buffered saline and collection by centrifugation.
Pellets were resuspended in a lysis buffer of 5 mM PIPES, 0.5% NP40 and 1% Complete Prote-
ase Inhibitor, incubated on ice for 10 m to extract nuclei by ultracentrifugation.After resuspen-
sion in nuclease lysis buffer of 50 mM Tris-HCl, 10 mM EDTA, 1% SDS and 1% Complete
Protease Inhibitor at pH 8.1, samples were again incubated on ice for 10 m prior to overnight
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storage at -80°C. Since KR12 formed alkylation adducts with DNA, crosslinking was not per-
formed during the DNA enrichment process. Genomic DNA was fragmented by sonication on
a Covaris M220 for two 10 m runs of 200 cycles (peak power of 75, duty level of 26) before pre-
cipitation in a solution of 300 mMNaOAc in 70% ethanol (JIS Special Grade, Wako) at 30°C
and isolation of genomic DNA by Micro-Vac evaporation (Tomy Digital Biology). Samples
were resuspended in nuclease-freewater (Millipore) for 15 m before collecting the supernatant
for enrichment with DynabeadsMyOne streptavidin C1 beads (Invitrogen) over 15 m. Beads
were washed twice in a buffer of 20 mMTris-HCl, 0.1% SDS, 1.1% Triton X-100, 2 mM EDTA
and 500 mMNaCl at pH 8.0, and five additional times in detergent-free buffer (5 mM Tris-
HCl, 0.5 mM EDTA, 1 M NaCl at pH 7.5) prior to elution with 2% SDS, 0.1 mMNaHCO3 and
3 mM biotin at 65°C for 4 h under agitation.
EnrichedDNA was purified by RNase A (5 μg, Invitrogen) for 10 m at 37°C, followed by
proteinase K (50 μg, Merck Millipore) treatment at 55°C for 40 m. Samples were mixed with
glycogen (Ambion), resuspended prior to phenol extraction. The supernatant was retained,
from the phenol layer, after centrifugation in 1:1 TE:NaCl and stored as aliquots in absolute
ethanol at -20°C prior to precipitation by centrifugation (17,000 × g, 4°C for 0.5 h). Samples
were evaporated in open atmosphere, reconstituted in 20 μL TE and quantified by Qubit 2.0
Fluorometer (ThermoFisher). Samples were end-repaired by 30 m incubation in the supplied
end-repair buffer and enzyme (2 μL) in Ion XpressTM Plus Fragment Library Preparation Kit;
the reactionmixtures were suspended with AMPure XP Reagent Beads (Agencourt), washed in
ethanol (70%) and eluted in Low TE buffer before adapter ligation for 30 m and again purified
with AMPure beads. Nick repair and amplification with Platinum PCR SuperMix High Fidelity
mix (ThermoFisher) proceeded at 72°C for nick repair (20 m), 95°C for denaturation (5 m), 18
cycles of 97°C denaturation, annealing at 60°C and 70°C extension (15 s, 15 s and 1 m, respec-
tively). Library preparation proceededwith 1.68 ng of enrichedDNA with Ion Plus Fragment
Library Kit (ThermoFisher) and AMPure XP Reagent Beads (Agencourt) per manufacturer’s
recommendations. Library sizes were validated on a Bioanalyzer 2100 (Agilent) and quantified
using the Ion LibraryQuantitation Kit (ThermoFisher); after emulsion PCR of the prepared
sample on Ion OneTouch 2 (ThermoFisher), a final quantity of 0.8 fmol DNA was used for
sequencing on an Ion Proton sequencer (ThermoFisher). Data acquisition and alignment to
hg19 genome were performed using Torrent Suite 5.0.4.
Differential Identification and Statistical Validation of KR12 Sites from
Sequencing Results
Ambiguous reads, i.e. mapping quality = 0, were removed from the BAM files before summa-
rizing base calls of aligned reads (mpileup) with samtools, with BAQs recalculated on the fly
and genotype likelihood output in uncompressed BCF format. Sequencing data (treatment and
control) were then converted to BED format before differential calling by diffReps with hg19 as
the genome size, method of chi-square, fragment size of 0 and no annotations; window sizes
varied from run to run within the range of 400–1200 bp. Sequences were regenerated over such
diffReps-assignedregions from the source FASTA file with indels ignored (see General
Computational Section), by bedtools, ignoring strand information. Matches to the KR12 motif
(“TGWWGGCGW” on the (+) strand), in both forward and reverse complementary orienta-
tions, were identified by searching against the reconstructed sequence files, followed by a back-
transformation to hg19 coordinates. Positions were again inspected against pileup results for
indels; sequences from such sites were reconstructed by variant calling with bcftools over given
regions by multi-allelic calling, with compressed output containing only variant sites. Indel
information was used to reconstruct a small region for motif searches and translated to hg19
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coordinates. Transcript positions and gene symbols from hg19 RefFlat (last accessed Feb 2015)
were used to generate an annotation including transcript locations and promoter regions,
defined as 1000 bp region upstream of transcription start site (TSS), based on RefFlat strand
information. KR12 candidates were subsequently annotated to produce a list of all positions of
candidate KR12 sites from sequencing results annotated by their respective gene or promoter
symbols.
For statistical validation, a list of nonbinding regions was generated by subtracting candidate
KR12 sites from the list of hypothetical sites via bedtools (removing entire feature if any overlap
was present). Randomizations were performed to generate null foreground and background
positions in R (sampling without replacement, with an equal number of null and candidate
sites). Per-base coverage was calculated over candidate regions as well as paired null foreground
and background regions from sequencing data, before unity normalization of each region. A dif-
ferential distribution was determined by subtracting per-base coverage between the input and
pulldown groups; for the null differential distributions, shuffling was performed to pair ran-
domly the null foreground with a background to increase randomness. For each of the candidate
differential distribution, two-sample Kolmogorov-Smirnov test was performed for each of the
null differential distribution under the hypothesis that there was no difference between the dis-
tributions; resultant p-values were adjusted for multiple comparisons by Benjamini-Hochberg
corrections. Statistical significancewas assessed based on the adjusted p-value at the 99.9th per-
centile against a pre-definedα-level of 0.05; sites with a p-value of 0.05< p< 0.055 were consid-
ered marginally significant and likewise annotated. Fold enrichment was calculated based on
the log2 ratio of the maximum coverage within a given window in the pulldown and input sam-
ples. Results frommultiple runs of varyingwindow sizes for diffRepswere compiled to produce
the final output of 3,343 KR12 binding sites.
Reverse-transcription Polymerase Chain Reaction
Cultures of 9.6 × 104 LS180 cells/well were treated with 500 nM KR12 for 6 h before RNA
extractionwith RNAeasy plus mini kit (Qiagen) and reverse transcription of 500 ng RNA to
cDNA by the SuperScript VILO cDNA Synthesis System (Invitrogen) for experiment as previ-
ously described [20]. Polymerase chain reactions were performedwith temperature cycles as
follows: 95°C, 2 m; (95°C, 30 s; 58°C, 30 s; 72°C, 30 s) over a number of optimized PCR cycles
(RPS18: 23 cycles;KRAS, PIK3CA,GUSB: 28 cycles); 72°C, 5 m, ending with holding at 4°C.
Primer sets used were as follows: KRAS, 5’-GGAGAGAGGCCTGCTGAA-3’ (sense) and 5’-
TGACCTGCTGTGTCGAGAAT-3’ (antisense); RPS18,5’-GAGGATGAGGTGGAACGTGT-3’
(sense) and 5’-TCTTCAGTCGCTCCAGGTCT-3’ (antisense); PIK3CA, 5’-AGTCGCCACC
TACCACAGAG-3’ (sense) and 5’-GCTGACCCTCATGGCTGT-3’ (antisense);GUSB, 5’-
GGTGGTTCATTGCTGCTGAC-3’ (sense) and 5’-TAGAACAGAGAGCGCCATTG-3’
(antisense).
Expression Microarrays
LS180 and SW480 cultures at 9.6 × 104 cells per sample were plated in a 6-well microtiter plate
for overnight attachment prior to treatment with 500 nMKR12 or 0.05% DMSO for 6 h. After
RNA extractionwith RNeasy Plus Mini Kit (Qiagen), samples at 100 ng were labeled with
RNA Spike-In Kit and analyzed on SurePrint G3 Human GE 8x60K V2 microarrays per Agi-
lent Technologies’ recommendations. Arrays with sample replicates (2 × 2 for LS180, 3 for
SW480) for each condition (DMSO, control; treatment, 500 nM KR12) were scanned on an
Agilent SureScanmicroarray scanner, with differential expressions calculated by the LIMMA
package [37] (background correction by the “normexp” method with an offset of 16, and scale-
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normalized for replicates between arrays). LIMMA calculated a linear model fit for each gene
and utilized the method of empirical Bayes for statistical evaluations and differential expres-
sions, with fold changes calculated from the difference betweenDMSO and KR12 treatments.
Spots with matching RefSeqmRNA and ncRNA identifiers were filtered and retained for sub-
sequent analyses. Statistical significance of gene expressions, unless otherwise specified,was
assessed by two-sample t-test under the null hypothesis that there was no difference between
their sample means against a predefined α-level of 0.05. For the purpose of comparison, genes
with promoter region (defined as 1000 bp upstream of transcription start site) binding were
also annotated with correspondingmRNA expressions.
Nucleosome Occupancy Profiling
DHS, H3K27Ac and nucleosome structure information were obtained as described in the Gen-
eral Computational Tools Section.ChromHMM tracks from eight cell lines (GM12878, H1
hESC, HepG2, HMEC, HSMM, K562, Nhek and Nhlf)were combined to identify common
overlaps, and heterochromatin regions with 5/8 overlaps were retained to create a consensus
heterochromatin track for comparison. LS180 H3K27Ac data were reprocessed in MACS 1.4.2
to generate a region file of signature peaks with default parameters and an effective genome
size of 2.7 × 109. H3K27Ac and KR12 binding sites were annotated to the closest transcript fea-
tures to facilitate the determination of two features occupying the same gene or otherwise, and
for each KR12 binding site assigned to a gene (or a promoter region), distance to the closest
H3K27Ac feature was determined similarly.
Gene Set Enrichment and Network Analysis
Gene set enrichment analysis was performedwith PANTHER 10.0 (May 15, 2015 release) sta-
tistical overrepresentation test, using the list generated from sequencing results as well as genes
belonging to the Ras pathway (hsa04014, KEGG [38, 39]) under default settings (predefinedα-
level of 0.05, Bonferroni corrections against a reference list of Homo sapiens genes). A list of
downregulated KR12-bound genes was selected by cross-referencingmicroarray expression
results for negative log2FC values for interaction analysis by STRING 10.0 with the following
parameters: highest confidence of 0.900, no additional nodes, custom limit of 0 interactors and
all active predictionmethods [40]. The resultant network was reconstructed in Cytoscape [41]
using STRING-computed combined scores, and sub-networks with nodes less than or equal to
four hidden for illustrative purposes.
KEGG Pathway Significance
The KEGGREST package [42] in R was used to acquire pathway-specific information from the
KEGG database. All 301 human pathways and corresponding gene lists were extracted from
KEGG. The gene lists were then compared against KR12 binding sites from LS180 sequencing
data to test for statistical significance in three different areas: 1) whether the mean gene expres-
sion in a given pathway compared to other genes was different; 2) whethermean expressions of
KR12-bound genes in that pathway was different from non-KR12-binding genes, and 3)
whethermean expressions of KR12-bound genes in the pathway were different from other
KR12-bound genes. Pathways with less than 2 KR12-binding genes are excluded from tests of
significance (81). For pathways satisfying all three criteria (9/220), they were considered candi-
dates for off-target pathways of KR12. Common (duplicate) KR12-bound genes from candidate
pathways were checked against all KEGG human pathways involving KRAS for possible
involvement to assess off-target effects of KR12.
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Prediction of hg19 binding sites of scrambled KR12 motifs
The last eight bases of the KR12 motif (TGWWGGCGW on the (+) strand) were randomly
scrambled for 100 permutations to check for genomic binding sites in hg19, with coding region
annotations extracted from the Table Browser from UCSC. To simulate 3’ adenine alkylation
by the conjugated seco-CBI moiety [43] for the scrambled 9-bp polyamides, the 5’ terminal thy-
mine was fixed for all 100 permutations. Counts for each motif were divided by the corre-
sponding KR12 value by the same metric.
Sequence similarity between KR12-bound non-coding RNA and KRAS
Annotations for lncRNA (colon lincRNA RNA-Seq Reads [44]) and miRNA (snoRNA and
miRNA [45]) were extracted from the Table Browser from UCSC and intersected with the list
of KR12 binding sites. Regions with at least 1 base overlap were retained and their sequences,
along with flanking up- and down-stream 1000 bp, were extracted from the LS180 genomic
sequence to generate a fasta file containing those 2009 bp regions for 9-mer composition analy-
sis by jellyfish [46] with an initial hash size of 3G. The KRAS transcript (chr12: 25357722–
25403865) was also extracted for comparison. Tantan [47] was used to performmasking of
simple repeats with the letter N.
Data Availability
Sequence read datasets for the KR12-enriched ("pulldown") and unenriched ("input") LS180
and SW480 genomes are available in the NCBI Sequence Read Archive (SRA) under BioProject
PRJNA342228; expression microarray datasets are available at the NCBI Gene Expression
Omnibus (NCBI GEO) database (accession number GSE86599).
Results and Discussion
Synthesis of KR12 and Cell Toxicity
We functionalized the original PIP (KR12 N/B) with biotin to create KR12 (Fig 1A) from a
modifiedFmoc solid-phase peptide synthesis procedure [20]. The one-pot preparation of
KR12 via the use of excess PyBOP to allow simultaneous activation of the polyamide backbone
C-terminus and biotin yielded the biotinylated intermediate 2, and the subsequent seco-CBI
coupling and liquid chromatography successfully afforded the final product (Fig 1B). Since
KR12 exhibited similar cell toxicity as the original PIP in LS180 cell lines (Fig 1C), we pro-
ceededwith ligand affinity-captured DNA from LS180 6 h after KR12 (500 nM) administration
for sequencing.
Design of Sequencing Pipeline
We then devised a method to enrich KR12-bound nucleotides to sequence for possible KR12
binding sites in the genome of LS180, a human colorectal cancer cell lines with KRAS G12V
mutation. Upon DNA extraction and fragmentation by sonication, KR12-alkylated nucleotides
underwent streptavidin enrichment and Ion Torrent sequencing to yield ~ 12 Gb per run of
sequencing data. Initial inspection showed a mixture of broad and narrow peaks that deviated
from typical TFBS ChIP-seq or histone modification, e.g. H3K36me3, experiments, and were
also uncharacteristic of DNase-seq [25, 48–50]. Since PIP-DNA interactions would have a
smaller binding surface than their protein-DNA counterparts, it was unclear whether popular
methods such as MACS or ZINBA would perform optimally with this dataset.
Additionally, our decision to omit formaldehyde crosslinking also attributed to the uncharac-
teristic peak distributions observed in the sequencing results. As the purpose of crosslinking was
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to preserve the interaction of DNA with protein targets, e.g. transcription factors, chromatin,
etc., via the formation of a methylene bridge between a nucleoside and a nucleophilic nitrogen
or sulfur of an amino acid, this additional step was unnecessarywith alkylating PIPs due to the
presence of an alkylating agent capable of forming a covalent linkage with the template 3’ termi-
nal adenine upon binding. Since concerns about the effectiveness of crosslinking to preserve all
protein-DNA ligands in certain cases had also been raised, e.g. [51], it was unclear whether the
Fig 1. Next-generation sequencing with biotinylated KR12. (A) Synthetic scheme of KR12 from the non-
biotinylated precursor KR12 N/B, with pyrroles and imidazoles colored in blue and red, respectively. (B) HPLC
retention time diagram (upper right) and mass spectrum (LC-MS) of KR12. (C) WST assay of LS180 cells at 300 and
1000 nM dosage of KR12 (black) compared to the non-biotinylated precursor (KR12 N/B, gray) and DMSO only
(white); error bars indicate ±1 SEM; n.s., no significance by two-sample Welch’s t-test.
doi:10.1371/journal.pone.0165581.g001
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added step will provide additional fidelity of securing polyamide-DNA interactions. The use of
formaldehyde would most likely crosslink DNA to chromatin and other transcription factors,
complicating analysis with alkylating polyamides. As previous methods, e.g., COSMIC [18], did
not describewhether it was possible to isolate polyamide binding sites outside chromatinized
regions, we decided to omit chemical crosslinking in this current procedure.
While ChIP-seq methods utilizing chemical crosslinking had been relatively mature and
widely adopted, PIP or non-crosslinking sequencing experiments were relatively rare and thus
less understood; as such, the extent of noise and peak qualities remained to be elucidated. Since
the effect of omitting chemical crosslinking on sequencing results was unclear, we devised a dif-
ferent approach to identify genomic regions enriched by KR12, initially deploying a sliding-
window comparison by diffReps [24] followed by a PIP-specific filtering process to find sites in
differentially enriched regions of the LS180 genome (Fig 2A). We reassembled genomic
sequences in the enriched peaks for matches to 5’-TGWWGGCGW-3’ (+), the KR12 9-bp
motif previously found to be a full-match binder by Bind-n-Seq analysis [19]. Following
sequence reassembly over indels frommulti-allelic variant calling, we designed an additional
statistical validation routine to determine whether candidates from peak calling did possess
sufficient experimental evidence to suggest enrichment over non-binding KR12 sites. While
the extra rigor might appear to be unnecessarily conservative and complicate the peak discov-
ery process, the added safeguard allowed us to approach the exclusion of a traditionally impor-
tant step more cautiously. We constructed a null background population consisting of
randomly sampled predicted KR12 sites based on motif matches in the hg19 genome for differ-
ential coverage comparison by two-sample Kolmogorov-Smirnov test, a non-parametric
method to account for possible deviations from normality in the heterogeneous peak distribu-
tions. After Benjamini-Hochberg corrections for multiple comparisons, we assessed statistical
significance for each candidate by their 99.9th-percentile adjusted p-value.
KR12 Binding in the Human Colorectal Cancer LS180 Genome
In total, we identified 3,343 KR12 binding sites (S1 Appendix; sample spectra in Fig 2B) in the
LS180 genome, compared to 29,263 hypothetical positions in hg19. Among those, 1,556 and 23
were located within the transcripts and promoter regions (defined here as 1,000 bp upstream of
transcription start site), respectively; 65 were on the list of 409 cancer-related genes [52]. These
numbers were in sharp contrast to a mere list of 20 sites by MACS (S1 Table); this level of under-
estimation also suggested the possibility of encountering an elevated level of false negatives
when adopting typical ChIP-seq procedures for PIP-based applications without modifications.
Presumably, this would becomemore apparent with longer PIPs when their longer base-pair
recognition and stronger interaction with DNA further reduced the number of possible sites.
As part of the validation, we performedPCR to check whether gene expressions of candidate
genes such as KRAS and PIK3CAwere disrupted by KR12 binding compared to sites that could
potentially be alkylated yet not found to do so, e.g.GUSB (Fig 2C). Reduced transcript levels
were indeed observed in KRAS and PIK3CAwhileGUSB and RPS18 failed to show discernible
differences. These results also indicated that the enzymatic repair step, performed during
sequencing but not PCR, did seem to restore the covalently modifiednucleotides to a
sequencer-compatible stage; this was evident from the presence of differential coverage and in
a previous report [19].
Effect of KR12 Binding on Gene Expressions and Implications on KRAS
Gene expression microarrays showed a significant difference in the mean expression of
KR12-bound genes (–log2FC of 0.658) and those without (0.339, Fig 3A left), echoing our
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Fig 2. KR12 binding in the human colorectal carcinoma LS180 genome. (A) Workflow to identify KR12 binding sites
in the LS180 genome by IonTorrent sequencing. Cells are administered with KR12 (500 nM, 6 h) prior to genomic DNA
extraction and fragmentation by sonication. Enrichment by streptavidin allows the capture of KR12-bound nucleotides. A
computational routine maps candidate regions in sequencing data, followed by site calling via motif matching and
statistical validation. Subsequent microarray analyses provide the means to confirm binding data with genome-level
changes. (B) Sample sequencing coverage of PIK3CA and KRAS, genes with KR12 binding sites (“KR12+”), and for
reference, a predicted site by motif matching but non-binding (“KR12–”) in GUSB; windows centered around a KR12 site
(black arrow, dashed line) are within –500 to +500 bp; blue and orange arrows indicate cumulative coverage for the
pulldown and input tracks, respectively. (C) Semi-quantitative PCR of RPS18, KRAS, PIK3CA and GUSB in the presence
of 500 nM KR12 or DMSO as control. “Motif match” and “binding” indicate whether a particular gene contains a
computationally predetermined match to the KR12 motif in the hg19 genome or a KR12 binding site determined by
sequencing analysis, respectively.
doi:10.1371/journal.pone.0165581.g002
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previous report that KR12 was capable of inducing toxicity in cancer cells. A significant
decrease over the nonbinding sites was also observed (Fig 3A right). Comparing expressions of
KR12-bound genes with all possible candidates prior to statistical validation also expectedly
showed distinguishable reductions (Fig 3B). Coupled with a priori knowledge from previous
Bind-n-Seq results [19], the workflow proposed here appeared to eliminate noise and false-pos-
itives by combining gene expressions. Further optimizations should allow us to address and
reduce the level of false-negatives in the form of rare mismatch binding events. While gene
expressions decreased upon KR12 binding, changes at the protein and subsequently the pheno-
typic levels were otherwiseminimal due to the small fraction (~10%) of binding sites within
protein coding regions. Comparing 9-mer frequencies of noncoding sections in the genome
(2,000 bp centered around KR12 sites within lncRNA) with the KRAS transcript showed a rela-
tive low number of sites (138) contained with stretches of lncRNA and suggested that the possi-
bility of KR12 affecting gene transcription via lncRNA interference was low, even given
sequence similarities at the 9-mer resolution between lncRNA and the KRAS transcript (S2
Appendix). Coupled with our previous observations that KR12 treatment led to a reduction in
Ras-GTP levels in vivo as well as phenotypic changes that were strongly Ras-dependent [20], it
appeared that while KR12 did have a number of possible genomic targets, cellular responses to
the polyamide remained overwhelmingly due to the transcriptional disruption of KRASmutant
codon 12. Previous results in which KR12 demonstrated appreciable toxicities in cell lines bear-
ing KRASG12D/G12Vmutations over cells with wild-type or non-D/Vmutations inferred the
possibility of KR12 effectively targeting the mutant driver gene.We tried to confirm our analyt-
ical procedure with the SW480 genome, in whichKRAS carried a homozygous codon 12 G12V
mutation (S3 Appendix). Under the same criteria, site characterization results showed degrees
of similarity between the makeup of KR12-bound genes in the two genomes and significance
between the expression of KR12-bound and unbound genes. Considering that the transcrip-
tomes of SW480 and LS180 were dynamic and thus understandably different, agreement
between the two mutant KRAS colorectal cancer genomes at the same time infers that the
approach can be extended to other genomes to identify binding sites by alkylating polyamides.
We then sought to understand if additional data exploration via interaction-association
pathway analyses and a series of statistical assessments could substantiate results obtained
from the workflow. From gene set enrichment analysis, we observedno statistical significance
in the mean expressions of KR12-bound genes or otherwise (Table 1; S1 Fig), indicating the
absence of specific effect by KR12 in those pathways despite enrichment. At the same time,
KR12-bound genes exhibited an entirely different makeup of pathway overrepresentation com-
pared to members of the Ras pathway (hsa04014 from KEGG). Expressions of KR12-bound
genes in other pathways were also evaluated (S2 Table), and while some pathways did exhibit
above-baseline changes in mean expressions, they frequently contained several common
KR12-bound genes (S3 Table) either associated with KRAS; e.g. SMURF2 [53], or participated
in the same pathways as KRAS. As such, expression changes in those pathways could also be
the consequence of KRAS inhibition. As such, these observationswould suggest that while
KR12 did bind non-KRAS sites non-systematically, most binding events appeared to be rela-
tively random and did not as a whole contribute to phenotypic changes to the extent that bind-
ing to KRASmutant codon 12. Network analysis of down-regulated genes (Fig 3C; S2 Fig)
revealed only a small number of direct interactions stemmed from KRAS, namely SPTBN1,
BCL2,TEK,KIT and PIK3CA. However, these first neighbors were heavily associated with
other down-regulated genes in the same network, corroborating previous findings that KR12
binding to KRASwould then induce changes along the downstream pathway cascades. From
these results, it appeared possible to use binding data with pathway information to generate
statistically based criteria to elucidate the extent of non-systematic binding of a PIP.
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Fig 3. Genome-wide effect of KR12 binding and implications of mutant codon 12 KRAS as a driver gene.
(A) Mean expressions (vertical axis,–log2FC) from RNA microarray analysis. Left: genome-wide KR12 binding
(KR12-bound ‘+’, black; otherwise ‘–’, gray); middle: genes with computationally predetermined motif matches (‘+’)
and those without (‘–’); right: expressions of genes with identified sites (‘+’) compared to genes with motif matches
but no binding (‘–’) as determined by the workflow. **, p < .01 from two-sample Welch’s t-test; error bars indicate
±1 SEM. (B) Mean expressions (–log2FC) of identified KR12-bound genes (“Post-validation”) compared to
candidate genes following sliding-window determination (“Pre-validation”); “Difference” indicates pre-validation
candidates not found in the Post-validation group. Error bars, ±1 SEM; **, p < .01 from two-sample Welch’s t-test.
(C) Interaction network of down-regulated KR12-bound genes. KRAS (black) and its first neighbors (blue, marked
with green arrows) are linked by solid black edges. Blue dashed edges indicate direct interactions with first
neighbors of KRAS.
doi:10.1371/journal.pone.0165581.g003
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Chromatin Accessibility and Other Implications
The broadened search space in our pipeline led us to explore chromatin accessibility in the con-
text of KR12 binding. Comparing site overlaps with DHS and heterochromatin mappings sug-
gested some propensity for KR12 to access condensed chromatin (Fig 4A; ~80% DHS and 65%
heterochromatin), a surprising departure from the earlier hypothesis of preferential binding in
loose chromatin [54]. A weak correlation between gene expression and the relative distance
fromH3K27Ac peaks for intragenic KR12 binding sites (Fig 4B) also suggested some degree of
binding independence from chromatin structure. Upon examining the expressions of 161 tran-
scription factors as listed in the ENCODE clustered transcription factor binding site data, we
found no significant differences in the mean or variance of expressions betweenKR12-bound
transcription factors or otherwise (p = 0.142 and p = 0.121 from two-sample t- and F-tests,
respectively); this further suggested that KR12 did not have a direct role in influencing large-
scale gene transcription. Furthermore, out of the 161 transcription factors, only 67 contained
predicted KR12 binding sites, and only 12 contained sites not located in the introns (S4 Table).
These observations echoed a recent proposal that sufficiently small transcription factors (~ 5
nm in diameter, or< 50 kDa) could penetrate and reorganize local chromatin structure to
enable transcription [55]. PIPs in general have molecular weights an order of magnitude lower
than the smallest transcription factors, and thus are able to bind its targets in condensed chro-
matin; nonetheless, their high affinity to DNA may still induce steric hindrance to hamper
transcription, leading to reduced expressions (Table 2). While such commonmeasures to pre-
dict chromatin accessibility were sufficiently reliable, the dynamic nature behind nucleosome
arrangement would still require further experimentation to verify so. Considering that previous
reports of chromatin accessibility experiments only utilized synthetic or purified nucleotides in
ex vivo settings, results here could potentially be one of the first sequencing- and expression-
based evidence of the genome-wide accessibility of PIP in living cells, which further improved
their attractiveness as therapeutic candidates than previously imagined.
As PIP binding appeared to be chromatin-independent and only weakly correlated with
transcriptional regulation, the disconnection between gene- and protein-level changes still
remained to be explored. A possibility raised in the earlier sectionwas the surprisingly small
number of binding sites in coding regions leading to fewer disruptions of changes at the protein
Table 1. Statistically overrepresented pathways for KR12-bound genes, compared to members in the Ras pathway (hsa04014) alone. Fold enrich-
ment between two groups have a χ2 statistic of 30.958 (p ~ 1.43 × 10−4).
Pathway KR12 Fold hsa04014 Fold
Histamine H1 receptor medicated signaling 9/1.75 5.15 6/0.31 19.22
VEGF signaling 13/3.55 3.66 31/0.63 48.82
Endothelin signaling 17/5.24 3.24 23/0.94 25.34
FGF signaling 23/7.41 3.10 58/1.32 43.82
Cadherin signaling 32/10.23 3.13 1/1.83[e] 0.55*
EGF receptor signaling 22/7.83 2.81 45/1.40 32.16
Gqα/Goα-mediated signaling 18/6.81 2.64 24/1.22 19.74
Wnt signaling 46/18.62 2.47 16/3.33 4.81
Unclassified 1012/1099.83 0.92 63/196.46 0.32
Pathway, overrepresented pathways determined using list of genes with KR12 binding sites via PANTHER, statistical criterion: p < .05 after Bonferroni
correction; KR12, Ratio of found/expected number of genes for those with KR12 binding sites compared to human genome; Fold, computed enrichment
fold; hsa04014, ratio of found/expected number of genes in the Ras pathway compared to human genome, irrespective of KR12 binding;
* Statistically insignificant (p ~ 1).
doi:10.1371/journal.pone.0165581.t001
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Fig 4. Chromatin accessibility of KR12. (A) Position-coverage plot of KR12 binding (9 bp per point, black and red)
in relation to DHS regions (10,000 bp per point, gray) per chromosome. Horizontal axes, relative position along
chromosome; vertical axes, relative coverage of a feature; for DHS regions, a coverage of 100% indicates that all
10,000 bp of a genomic region have DHS, while for KR12 sites, black spots (0%) indicate that a particular site is
outside the boundaries of a DHS region, in contrast to the red sites (> 0%). (B) Gene expressions (vertical,–log2FC) as
a function of KR12 site proximity (horizontal, 1000 bp) to the histone modification feature H3K27Ac. Spearman’s
correlation coefficient (ρ = –0.171) suggests a weak correlation with histone modification. (C) Comparison of predicted
binding site counts in coding regions (CDS) and in the hg19 genome for KR12 (red) against 100 randomly selected
motifs (black, see S4 Table); horizontal axis, ratio of binding sites per motif/KR12 binding sites; vertical axis, ratio of
binding sites in CDS per motif/KR12. Dashed line with slope of 1 (gray) is provided as reference.
doi:10.1371/journal.pone.0165581.g004
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level. We then compared the total number of possible binding sites in the hg19 genome for
KR12 against 100 randomly scrambledmotifs revealed a relatively small number of binding
sites (~ 30 percentile) and a small fraction of coding regions (~ 43 percentile, Fig 4C); KR12’s
relatively infrequent binding in the coding region could attribute to some extent the discrimi-
nating toxicity it had on cell lines with G12D/G12Vmutations over wild-type.
The concept of “oncogenic addiction,” in which tumors relied on one dominant oncogene,
e.g.KRAS, for growth and survival [56], has been advocated as possible approaches to molecu-
lar therapy; as such, the use of KR12 presents a viable option for treating mutant KRAS geno-
types.While alkylation of occupied sites by KR12 did contribute to DNA damage and reduced
gene expressions, the relatively few binding sites in promoter and coding regions perhaps
explained the highly specific and directed suppression of mutant KRAS codon 12 by the poly-
amide. The relatively small subset of genomic binding by KR12 in contrast to the nonspecific
alkylation of guanines and adenines by conventional alkylating neoplastic agents such as mel-
phalan or mechlorethamine [57] could also lead to a potential reduction in the amount of
adverse side effects. As more applications of PIP are explored, the need for similar sequencing
and expression-driven exploratory analyses will also rise; incorporation of the workflow herein
could then enhance the throughput of designing and optimizing new and existing polyamide
designs, especially with further optimizations in the enrichment procedure and computational
peak identification.
Conclusion
The use of biotinylated alkylating polyamides in next-generation sequencing, followed by Kol-
mogorov-Smirnov-validated sliding-window enrichment identification and statistical assess-
ment of coupled site-expression microarray data, provides a workflow to characterize possible
genome-wide effect of a PIP. Assessment of statistically significant pathways based on the
impact of PIP binding, intra-association of genes with binding sites in a network analysis as
well as chromatin accessibility and coding-regionbinding frequencies also provide a basis of
decidingwhether a polyamide will have large-scale genetic level effects as well. The analytical
steps proposed in this workflow are sufficientlymodular and implementable in-line with an
existing PIP design protocol.
While the identification of KR12 binding sites in the LS180 genome suggested that PIP
binding was not unique only to the oncogene, evaluation of gene expressions and pathway
analyses revealed that such binding events appeared to be non-systematic. In conjunction to
previous reports where KR12 exerted toxicity against specificmutant cancer cell lines and dem-
onstrate changes in cell cycle, it also suggested that non-KRAS binding overall had little contri-
bution to changes at the phenotypic level.
Table 2. Expressions and distributions of KR12 binding in local chromatin structures.
DHS LS180 hg19 p-value Heterochromatin LS180 hg19 p-value
Chromatin Ratio 0.245 0.353 4.33×10−189 Chromatin Ratio 0.529 0.692 5.34×10−138
LC+ -0.768 -0.508 6.10×10−5 LC+ -1.029 -0.672 9.40×10−15
LC– -0.653 -0.579 3.77×10−2 LC– -0.250 -0.212 n.s.
Chromatin ratio, odds of loose/condensed chromatin for DHS (within/outside) and heterochromatin (outside/inside); LC+ and LC–, mean expressions of
KR12-bound genes in loose and condensed chromatin, respectively; corresponding values from hg19 predictions are listed as reference. Statistical
significance between experiment (LS180) and predictions (hg19) is assessed by Welch’s two-sample t-test. p-value is estimated from 1000 bootstrapping
trials of n = 100; n.s., not significant.
doi:10.1371/journal.pone.0165581.t002
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